



Inotrem appoints Laurent Vincens as Chief Technology Officer and Head of Manufacturing

Paris, March 17, 2022. [Inotrem](#), an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Laurent Vincens as Chief Technology Officer and Head of Manufacturing. The newly created position comes as the company is rapidly advancing its TREM-1 pathway focused drug development programs.

Reporting to Sven Zimmermann, Inotrem's CEO, Mr Vincens will have responsibility for all drug substance and drug product activities from pre-clinical development, through clinical supplies to registration studies and commercial supplies. Mr Vincens will also represent the company as its CMC expert in meetings with U.S. and European regulatory authorities.

Mr Vincens brings twenty years of leadership experience in biologics development, large scale manufacturing and commercial launches. Before joining Inotrem, he was Head of Product Development & Production at Stallergenes Greer, with oversight of the French production sites. Prior to that, he spent a decade at UCB Farchim in Switzerland where he led major projects to either create or diversify manufacturing and supply chains for marketed drugs across the EU, the United States and other markets. He started his career in GMP manufacturing at Pierre Fabre. He is an engineer and pharmacist by training; and holds a PharmD from the Faculté de Pharmacie of the Université de Lorraine, and a Master of Engineering from ENSIC in Nancy.

Sven Zimmermann, CEO at Inotrem, shares: *"It is with great enthusiasm that we welcome Laurent. With his broad, international experience in pharmaceutical development and drug manufacturing, he will bring valuable expertise to Inotrem. He will contribute significantly to the execution of our strategic plan as we expand our pipeline to new assets and approach registration trials with our lead asset in septic shock and severe forms of COVID-19".*

Laurent Vincens, Chief Technology Officer and Head of Manufacturing at Inotrem, adds: *"I am excited to join Inotrem and help advance the programs in septic shock and in severe forms of Covid-19 as well as the early monoclonal antibody-based programs. Inotrem has developed world-class scientific leadership around the TREM-1 pathway and I look forward to joining them in bringing groundbreaking solutions to patients suffering from acute and chronic inflammatory conditions".*

About Inotrem

Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com

Media contact for Inotrem

Anne REIN

Strategies & Image (S&I)

anne.rein@strategiesimage.com

+33 6 03 35 92 05